Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | HTR7 | P34969 | 4/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23701405 | 0.88 | KDM4E (0.40) | HRH3HTR7TMEM97MAPTGAA | |
| SCHEMBL23701403 | 0.88 | KDM4E (0.40) | HRH3HTR7TMEM97MAPTGAA | |
| SCHEMBL27399973 | 0.80 | HTR7 (0.46) | HRH3HTR7TMEM97MAPTMEN1 | |
| SCHEMBL23701421 | 0.79 | KDM4E (0.42) | HTR7TMEM97MAPTGAAHTT | |
| SCHEMBL23701422 | 0.79 | KDM4E (0.42) | HTR7TMEM97MAPTGAAHTT | |
| SCHEMBL23701485 | 0.78 | ACACB (0.44) | HRH3HTR7TMEM97MAPTGAA | |
| SCHEMBL23701487 | 0.78 | ACACB (0.44) | HRH3HTR7TMEM97MAPTGAA | |
| SCHEMBL22567361 | 0.74 | HRH3 (0.40) | HRH3DRD2DRD3KCNH2KDM4E | |
| SCHEMBL23701443 | 0.71 | HTR7 (0.37) | HRH3HTR7TMEM97 | |
| SCHEMBL23701444 | 0.71 | HTR7 (0.37) | HRH3HTR7TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | HRH3 523/4885HTR7 2686/4885TMEM97 2345/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | HRH3 523/4885HTR7 2686/4885TMEM97 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.